Phase 2 PLEIADES Study: How This Affects Clinicians?

Phase 2 PLEIADES Study: How This Affects Clinicians?

Mount Sinai Health System

3 months
5 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Ajai Chari, MD of @MountSinaiNYC answers how the phase 2 PLEIADES study affects treatment and clinicians today.

____________

About the PLEIADES Trial2 
The non-randomized, open-label, parallel assignment Phase 2 PLEIADES (MMY2040) study included 199 adults with either newly diagnosed or relapsed/refractory multiple myeloma. Patients with newly diagnosed multiple myeloma were treated with 1,800 mg of the SC formulation in combination with either bortezomib, lenalidomide and dexamethasone (D-VRd) or bortezomib, melphalan and prednisone (D-VMP). Patients with relapsed or refractory disease were treated with 1,800 mg of the SC formulation plus lenalidomide and dexamethasone (D-Rd). The primary endpoint for the D-VMP and D-Rd cohorts was overall response rate. The primary endpoint for the D-VRd cohort was very good partial response or better rate. An additional cohort of patients with relapsed and refractory multiple myeloma treated with daratumumab plus carfilzomib and dexamethasone was subsequently added to the study.

Read here: https://www.oncologytube.com/video/new-darzalex-daratumumab-data-from-griffin-study-show-high-response-rate-and-depth-of-response-in-patients-with-newly-diagnosed-multiple-myeloma-who-are-transplant-eligible

Up Next Autoplay
Multiple Myeloma Disparities #ASH19 @WinshipAtEmory
Multiple Myeloma Disparities #ASH19 @WinshipAtEmory
Category: Multiple Myeloma
23 Views
ash 4 weeks
GRIFFIN Study Update #ASH19 @LevineCancer
GRIFFIN Study Update #ASH19 @LevineCancer
Category: Multiple Myeloma
3 Views
ash 1 month
Phase 1 Clinical Study (CRB-402) of bb21217 #ASH19 @BerdejaJesus
Phase 1 Clinical Study (CRB-402) of bb21217 #ASH19 @BerdejaJesus
Category: Multiple Myeloma
11 Views
ash 1 month
ICARIA-MM: What's Next? #ASH19
ICARIA-MM: What's Next? #ASH19
Category: Multiple Myeloma
6 Views
ash 1 month
ICARIA-MM #ASH19
ICARIA-MM #ASH19
Category: Multiple Myeloma
24 Views
ash 1 month
RRMM Patients Treated with IRd: How This Affects Clinicians #ASH19 @TakedaOncology
RRMM Patients Treated with IRd: How This Affects Clinicians #ASH19 @TakedaOncology
Category: Multiple Myeloma
6 Views
ash 1 month
Outcomes in RRMM Patients Treated with IRd #ASH19 @TakedaOncology
Outcomes in RRMM Patients Treated with IRd #ASH19 @TakedaOncology
Category: Multiple Myeloma
5 Views
ash 1 month
MAIA Study Update #ASH19
MAIA Study Update #ASH19
Category: Multiple Myeloma
40 Views
ash 1 month
HORIZON Study #ASH19 @RushMedical
HORIZON Study #ASH19 @RushMedical
Category: Multiple Myeloma
19 Views
ash 1 month
Phase I Study Evaluating NKTR-255 in MM and NHL #ASH #ASH19 @DanaFarber
Phase I Study Evaluating NKTR-255 in MM and NHL #ASH #ASH19 @DanaFarber
Category: Multiple Myeloma
11 Views
ash 1 month